Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Symphogen, a Danish developer of antibody therapeutics, has started a single arm, multi-center and open label Phase 2 clinical trial to evaluate the efficacy and safety of Sym004.
Subscribe to our email newsletter
The trial will evaluate Sym004 in patients suffering from recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
The Phase 2 trial aims at progression free survival at 24 weeks.
Symphogen CEO Kirsten Drejer said they are very excited about advancing this compound into clinical evaluation for treatment of SCCHN as well as mCRC in patients who have failed anti-EGFR antibody based therapy.